Madhoo, M., Roth, R. M., Keefe, R. S. E., Sambunaris, A., Scheckner, B., Nielsen, J., … Lasser, R. (2012). P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels. In European Neuropsychopharmacology (Vol. 22, pp. S233–S234). Elsevier BV. https://doi.org/10.1016/s0924-977x(12)70346-2

Madhoo, M., R. M. Roth, R. S. E. Keefe, A. Sambunaris, B. Scheckner, J. Nielsen, B. Adeyi, J. Wu, and R. Lasser. “P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels.” In European Neuropsychopharmacology, 22:S233–34. Elsevier BV, 2012. https://doi.org/10.1016/s0924-977x(12)70346-2.

Madhoo M, Roth RM, Keefe RSE, Sambunaris A, Scheckner B, Nielsen J, et al. P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels. In: European Neuropsychopharmacology. Elsevier BV; 2012. p. S233–4.

Madhoo, M., et al. “P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels.” European Neuropsychopharmacology, vol. 22, Elsevier BV, 2012, pp. S233–34. Crossref, doi:10.1016/s0924-977x(12)70346-2.

Madhoo M, Roth RM, Keefe RSE, Sambunaris A, Scheckner B, Nielsen J, Adeyi B, Wu J, Lasser R. P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels. European Neuropsychopharmacology. Elsevier BV; 2012. p. S233–S234.